Literature DB >> 28496905

Role of Bi-Atrial Pacing In Slowing The Progression of Paroxysmal Atrial Fibrillation To Permanent Atrial Fibrillation.

Raffaele Corbisiero1, Kathleen Zazzali1, David Muller1.   

Abstract

Introduction: Bi-atrial lead placement combined with atrial overdrive pacing has demonstrated a reduction in percent time mode switched and mode switches per day. This retrospective analysis compared long term outcomes of patients with right atrial overdrive pacing alone (DAO) to patients having atrial overdrive with bi-atrial leads (BIA) in slowing the progression of paroxysmal atrial fibrillation (PAF) to permanent continuous atrial fibrillation (CAF).
Methods: Thirty-three patients age 76.6 (+/-1.96) from our prior investigation were selected. The DAO control group (N=16) had received a standard right atrial pacing lead. The BIA group (N=17) had pacing leads placed in the right atrium and coronary sinus. Patients were followed for a mean 1217 days (+/-838). Days of CAF was classified as the date of final mode switch until analysis.
Results: A total of 40,171 follow-up days were evaluated. The mean follow-up for both cohorts was 1217 days (+/-838). The DAO group consisted of 15,318 days (mean 957 +/-761) and the BIA group 24,853 days (mean 1461 +/-854). A lower total number of days were spent in CAF in the BIA group versus the DAO group, 1380 vs 2197 respectively. Corrected for follow-up duration, 5.55% days in CAF was seen in the BIA group vs. 14.34% in the DAO group which did not reach statistical significance. Conclusions: Although BIA overdrive pacing initially demonstrated reduced time in mode switch compared to DAO alone, this analysis did not detect a reduction in progression to CAF. More subjects or a longer follow up would be needed.

Entities:  

Keywords:  Atrial Fibrillation; Bi-Atrial pacing; Overdrive pacing

Year:  2013        PMID: 28496905      PMCID: PMC5153129          DOI: 10.4022/jafib.856

Source DB:  PubMed          Journal:  J Atr Fibrillation        ISSN: 1941-6911


  30 in total

1.  Management of atrial fibrillation--radical reform or modest modification?

Authors:  Rodney H Falk
Journal:  N Engl J Med       Date:  2002-12-05       Impact factor: 91.245

2.  Coronary sinus pacing prevents induction of atrial fibrillation.

Authors:  P Papageorgiou; F Anselme; C J Kirchhof; K Monahan; C A Rasmussen; L M Epstein; M E Josephson
Journal:  Circulation       Date:  1997-09-16       Impact factor: 29.690

3.  Comparisons of oral propafenone and sotalol as an initial treatment in patients with symptomatic paroxysmal atrial fibrillation.

Authors:  S H Lee; S A Chen; C T Tai; C E Chiang; Z C Wen; Y J Chen; W C Yu; J L Huang; A N Fong; J J Cheng; M S Chang
Journal:  Am J Cardiol       Date:  1997-04-01       Impact factor: 2.778

4.  Interatrial septum pacing: a new approach to prevent recurrent atrial fibrillation.

Authors:  L Padeletti; M C Porciani; A Michelucci; A Colella; P Ticci; S Vena; A Costoli; C Ciapetti; P Pieragnoli; G F Gensini
Journal:  J Interv Card Electrophysiol       Date:  1999-03       Impact factor: 1.900

5.  Prevention of chronic atrial fibrillation by pacing in the region of Bachmann's bundle: results of a multicenter randomized trial.

Authors:  S J Bailin; S Adler; M Giudici
Journal:  J Cardiovasc Electrophysiol       Date:  2001-08

6.  Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation.

Authors:  S C Reimold; C O Cantillon; P L Friedman; E M Antman
Journal:  Am J Cardiol       Date:  1993-03-01       Impact factor: 2.778

Review 7.  The results of pacing trials for the prevention and termination of atrial tachyarrhythmias: is there any evidence of therapeutic breakthrough?

Authors:  Irina Savelieva; A John Camm
Journal:  J Interv Card Electrophysiol       Date:  2003-04       Impact factor: 1.900

Review 8.  Atrial septal pacing: a new approach to prevent atrial fibrillation.

Authors:  Luigi Padeletti; Antonio Michelucci; Paolo Pieragnoli; Andrea Colella; Nicola Musilli
Journal:  Pacing Clin Electrophysiol       Date:  2004-06       Impact factor: 1.976

9.  Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter. The Flecainide Multicenter Atrial Fibrillation Study Group.

Authors:  G V Naccarelli; P Dorian; S H Hohnloser; P Coumel
Journal:  Am J Cardiol       Date:  1996-01-25       Impact factor: 2.778

10.  Safety of long-term flecainide and propafenone in the management of patients with symptomatic paroxysmal atrial fibrillation: report from the Flecainide and Propafenone Italian Study Investigators.

Authors:  M Chimienti; M T Cullen; G Casadei
Journal:  Am J Cardiol       Date:  1996-01-25       Impact factor: 2.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.